This document relates generally to cardiac pacing systems and particularly to a system for delivering pacing pulses during a revascularization procedure.
The heart is the center of a person's circulatory system. It includes an electro-mechanical system performing two major pumping functions. The left portions of the heart draw oxygenated blood from the lungs and pump it to the organs of the body to provide the organs with their metabolic needs for oxygen. The right portions of the heart draw deoxygenated blood from the body organs and pump it to the lungs where the blood gets oxygenated. These pumping functions are resulted from contractions of the myocardium (cardiac muscles). In a normal heart, the sinoatrial node, the heart's natural pacemaker, generates electrical impulses, called action potentials, that propagate through an electrical conduction system to various regions of the heart to excite the myocardial tissues of these regions. Coordinated delays in the propagations of the action potentials in a normal electrical conduction system cause the various portions of the heart to contract in synchrony to result in efficient pumping functions. A blocked or otherwise abnormal electrical conduction and/or deteriorated myocardial tissue cause dyssynchronous contraction of the heart, resulting in poor hemodynamic performance, including a diminished blood supply to the heart and the rest of the body. The condition where the heart fails to pump enough blood to meet the body's metabolic needs is known as heart failure.
Myocardial infarction (MI) is the necrosis of portions of the myocardial tissue resulted from cardiac ischemia, a condition in which the myocardium is deprived of adequate oxygen and metabolite removal due to an interruption in blood supply caused by an occlusion of a blood vessel such as a coronary artery. The necrotic tissue, known as infarcted tissue, loses the contractile properties of the normal, healthy myocardial tissue. Consequently, the overall contractility of the myocardium is weakened, resulting in an impaired hemodynamic performance. Following an MI, cardiac remodeling starts with expansion of the region of infarcted tissue and progresses to a chronic, global expansion in the size and change in the shape of the entire left ventricle. The consequences include a further impaired hemodynamic performance and a significantly increased risk of developing heart failure.
When a blood vessel such as the coronary artery is partially or completely occluded, a revascularization procedure such as percutaneous transluminal coronary angioplasty (PCTA) can be performed to reopen the occluded blood vessel. However, the revascularization procedure itself involves a temporary occlusion of the coronary artery. In addition, plaques dislodged and displaced by the revascularization procedure may enter small blood vessels branching from the blood vessel in which the revascularization is performed, causing occlusion of these small blood vessels. This complication is referred to as “snow plow effect.” The revascularization procedure may also cause distal embolization, i.e., obstruction of the artery caused by the plaque dislodged during the procedure. The temporary occlusion, snow plow effect, and distal embolization may each cause cardiac injuries such as further expansion of the region of infarcted tissue. In addition, the revascularization procedure is known to increase the risk for occurrences of arrhythmia.
Therefore, there is a need for minimizing cardiac injury and preventing arrhythmias during the revascularization procedure.
Cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia associated with an ischemic event including the occlusion of a blood vessel during a revascularization procedure. Pacing pulses are generated from a pacemaker and delivered through one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device used in the revascularization procedure. The pacemaker generates the pacing pulses according to a predetermined cardiac protection pacing sequence before, during, and/or after the ischemic event.
In one embodiment, a pacemaker includes a pacing output circuit and a control circuit. The control circuit includes a cardiac protection pacing sequence timer that times a predetermined cardiac protection pacing sequence. The predetermined cardiac protection pacing sequence includes alternating pacing and non-pacing periods. The pacing periods each have a predetermined pacing duration during which a plurality of pacing pulses are delivered from the pacing output circuit in a predetermined pacing mode. The non-pacing periods each have a predetermined non-pacing duration during which no pacing pulse is delivered.
In one embodiment, a PTVI device includes a proximal end portion, a distal end portion, and an elongate body. The proximal end portion includes one or more connectors for connecting to a pacemaker. The distal end portion is configured for intravascular placement. The elongate body is coupled between the proximal end portion and the distal end portion. One or more pacing electrodes are incorporated onto the distal end portion. One or more conductors within the elongate body each connect one of the one or more pacing electrodes to one of the one or more connectors. In a further embodiment, the distal end portion includes a tip and an angioplasty device. The angioplasty device has one end approximately adjacent to the tip and another end coupled to the elongate body.
In one embodiment, a method for operating a system providing for cardiac protection pacing is provided. A predetermined pacing sequence is timed. The predetermined pacing sequence includes alternating pacing and non-pacing periods. The pacing periods each have a predetermined pacing duration during which a plurality of pacing pulses are delivered in a predetermined pacing mode. The plurality of pacing pulses are delivered to one or more pacing electrodes incorporated onto a PTVI device.
In one embodiment, a method for making a PTVI device is provided. The PTVI device has a distal end portion configured for intravascular placement. One or more pacing electrodes are incorporated onto that distal end portion.
This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects of the invention will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof. The scope of the present invention is defined by the appended claims and their legal equivalents.
The drawings illustrate generally, by way of example, various embodiments discussed in the present document. The drawings are for illustrative purposes only and may not be to scale.
In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their legal equivalents.
It should be noted that references to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment.
This document discusses a pacing system for minimizing damage to the myocardial tissue and preventing arrhythmias during a revascularization procedure that requires temporary occlusion of one or more blood vessels. In a specific application, this system provides for cardiac protection pacing during a percutaneous transluminal coronary angioplasty (PTCA) procedure. Cardiac protection pacing includes the delivery of a pacing therapy before, during, and/or after the temporary occlusion of a coronary artery associated with the PTCA procedure, for preventing or reducing adverse effects of the occlusion, which is an ischemic event. The pacing therapy can be delivered at almost any time during a revascularization procedure, as soon as pacing electrodes are in place, without substantially interfering with the revascularization procedure.
To deliver pacing pulses during a revascularization procedure, one or more pacing electrodes are incorporated onto the distal end portion of a PTVI device. Examples of such PTVI device include guide wires, dilatation balloon catheters, stent delivery systems, brachytherapy devices, atherectomy devices, distal embolization protection devices, and guiding catheters. A pacemaker is connected to the proximal end portion of the PTVI device to deliver the pacing pulses to the heart through the one or more electrodes. In one embodiment, the pacemaker is an external pacing device such as a pacing system analyzer. This approach to cardiac protection pacing allows delivery of pacing pulses as soon as the PTVI device is inserted.
PTVI device 110 is used during a revascularization procedure and includes a distal end portion 111 for intravascular placement and a proximal end portion 112. Proximal end portion 112 includes a proximal end device 114 and pacing connectors 116 and 117. Proximal end device 114 includes various connectors and other structures allowing manipulation of PTVI device 110 including the percutaneous transluminal insertion of the device and operation of an angioplasty device at distal end 111. Pacing connectors 116 and 117 provide for electrical connections between cable 125 and PTVI device 110. In one embodiment, as illustrated in
Distal end portion 111 of PTVI device 110 includes one or more pacing electrodes to allow pacing pulses to be delivered to a heart 101 during the PTCA procedure. In one embodiment, pacing pulses are delivered through two pacing electrodes on distal end portion 111 of PTVI device 110. In another embodiment, pacing pulses are delivered through a pacing electrode on distal end portion 111 of PTVI device 110 and surface electrode 122 functioning as the return electrode for pacing.
Pacemaker 130 delivers pacing pulses by following a cardiac protection pacing sequence. In one embodiment, the cardiac protection pacing sequence provides for cardiac protection pacing following an ischemic event to prevent arrhythmias and cardiac injuries caused by the ischemic event. In one embodiment, pacemaker 130 is an external pacemaker such as a pacing system analyzer (PSA). In another embodiment, pacemaker 130 includes an implantable pacemaker adapted for external use.
It is to be understood that
Pacing output circuit 232 delivers pacing pulses to PTVI device 110 through cable 125. Control circuit 234 controls the delivery of the pacing pulses. In one embodiment, as illustrated in
In the embodiment illustrated in
In various other embodiments, the cardiac protection pacing sequence includes pacing at one or more atrial tracking or other pacing modes. Examples of pacing modes used in such a cardiac protection pacing sequence include VDD, VVI, and DDD modes. In various embodiments, the VVI and DDD modes are delivered with a lower rate limit higher than the patient's intrinsic heart rate. In one embodiment, pacing therapy is delivered to prevent restenosis. In another embodiment, pacing therapy is delivered to treat an arrhythmia during the revascularization procedure, for example, when the patient experiences bradycardia during the procedure.
In one embodiment, the pacing pulses are delivered according to the cardiac protection pacing sequence through PTVI device 110 during the revascularization procedure. After the revascularization procedure, if an implantable pacemaker is implanted into the patient, pacing therapy is delivered to heart 101 through one or more implantable leads from the implantable pacemaker. The pacing therapy includes delivering pacing pulses according to a pacing sequence that is substantially identical or similar to the cardiac protection pacing sequence applied during the revascularization procedure. The pacing sequence is delivered according to a predetermined schedule, such as on a predetermined periodic basis. This prevents or reduces possible cardiac injury after the revascularization, including cardiac injury and occurrences of arrhythmia caused by ischemic events including myocardial infarction that may be experienced by the patient after the implantation of the implantable pacemaker.
In one embodiment, elongate body 450 is an elongate cylindrical shaft having a diameter in a range of approximately 0.2 mm to 1.5 mm, and PTVI device 410 has a length in a range of approximately 30 cm to 300 cm. In another embodiment, elongate body 450 is an elongate tubular body having an outer diameter in a range of approximately 0.5 mm to 8 mm and an inner diameter (of a lumen) in a range of approximately 0.4 mm to 7 mm. In one embodiment, PTVI device 410 is a guide wire such as a coronary guide wire. PTVI device 410 is formed by conductor 456, which is insulated throughout its length except for pacing electrode 454 and connector 458. As the core of the guide wire, conductor 456 is made of a metallic material such as stainless steel, alloys of nickel, titanium, and cobalt, and is insulated with a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE). Electrode 454 is made of a metallic material such as platinum, and iridium alloy. In another embodiment, conductor 456 is a metal wire other than the core of the guide wire. In another embodiment, PTVI device 410 is a guiding catheter such as a coronary guiding catheter. The coronary guiding catheter includes an elongate tubular body with a lumen extending between distal end portion 452 and proximal end portion 452. In another embodiment, PTVI device 410 includes two or more electrodes in distal end portion 451 and two or more conductors each connected between one of the electrodes and connector 458, which is a multi-conductor connector allowing for two or more electrically insulated connections.
In one embodiment, elongate body 550 is an elongate cylindrical shaft having a diameter in a range of approximately 1 mm to 5 mm. PTVI device 510 has a length in a range of approximately 50 cm to 150 cm. In one embodiment, angioplasty device 560 has a fixed, substantially cylindrical shape with a diameter in a range of approximately 1 mm to 10 mm. In another embodiment, angioplasty device 560 has an adjustable, substantially cylindrical or semi-spherical shape with a maximum diameter in a range of approximately 1 mm to 10 mm when fully expanded and a maximum diameter in a range of approximately 0.5 mm to 5 mm when fully contracted. In one embodiment, PTVI device 510 is a PTCA catheter and includes a lumen longitudinally extending within elongate body 550 to accommodate at least a portion of a guide wire such as PTVI device 410. In one embodiment, conductors 556A and 556B are each made of a metallic material such as stainless steel and alloys of nickel, titanium, and cobalt. Electrodes 554A and 554B are each made of a metallic material such as platinum, and iridium alloy. Elongate body 550 has a tubular outer shell made of a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE).
In one alternative embodiment, PTVI device 510 includes one electrode in distal end portion 551 and one conductor connected between that electrode and a pacing connector in proximal end portion 552. In another alternative embodiment, PTVI device 510 includes three or more electrodes in distal end portion 551 and three or more conductors each connected between one of the electrodes a pacing connector in proximal end portion 552.
PTVI devices 410, 510, and 610 are illustrated in
It is to be understood that the above detailed description, including the various configurations of PTVI devices, is intended to be illustrative, and not restrictive. In general, cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia caused by an ischemic event by using one or more pacing electrodes incorporated onto any intravascular device and a pacemaker that is capable of delivering pacing pulses according to a predetermined cardiac protection pacing sequence. Other embodiments will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
This application is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 11/113,828, filed on Apr. 25, 2005, now issued as U.S. Pat. No. 7,962,208, which is hereby incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3769984 | Muench | Nov 1973 | A |
3837347 | Tower | Sep 1974 | A |
3865118 | Bures | Feb 1975 | A |
3893461 | Preston | Jul 1975 | A |
3915174 | Preston | Oct 1975 | A |
3942536 | Mirowski et al. | Mar 1976 | A |
3949757 | Sabel | Apr 1976 | A |
4030508 | Thalen | Jun 1977 | A |
4094321 | Muto | Jun 1978 | A |
4124031 | Mensink et al. | Nov 1978 | A |
4136702 | Trabucco | Jan 1979 | A |
4202339 | Wirtzfeld et al. | May 1980 | A |
4262982 | Kenny | Apr 1981 | A |
4365639 | Goldreyer | Dec 1982 | A |
4388930 | De Bellis | Jun 1983 | A |
4587975 | Salo et al. | May 1986 | A |
4702253 | Nappholz et al. | Oct 1987 | A |
4763655 | Wirtzfeld et al. | Aug 1988 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4834710 | Fleck | May 1989 | A |
4882777 | Narula | Nov 1989 | A |
4919133 | Chiang | Apr 1990 | A |
4955382 | Franz et al. | Sep 1990 | A |
4962767 | Brownlee | Oct 1990 | A |
5007427 | Suzuki et al. | Apr 1991 | A |
5025786 | Siegel | Jun 1991 | A |
5072458 | Suzuki | Dec 1991 | A |
5099839 | Miyata et al. | Mar 1992 | A |
5111818 | Suzuki et al. | May 1992 | A |
5121750 | Katims | Jun 1992 | A |
5127403 | Brownlee | Jul 1992 | A |
5131406 | Kaltenbach | Jul 1992 | A |
5143089 | Alt | Sep 1992 | A |
5154169 | Miyata et al. | Oct 1992 | A |
5154387 | Trailer | Oct 1992 | A |
5156157 | Valenta, Jr. et al. | Oct 1992 | A |
5170802 | Mehra | Dec 1992 | A |
5261419 | Osypka | Nov 1993 | A |
5285781 | Brodard | Feb 1994 | A |
5314460 | Borghi | May 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5336251 | Borghi | Aug 1994 | A |
5356427 | Miyata et al. | Oct 1994 | A |
5374287 | Rubin | Dec 1994 | A |
5387232 | Trailer | Feb 1995 | A |
5411535 | Fujii et al. | May 1995 | A |
5423806 | Dale et al. | Jun 1995 | A |
5466255 | Franchi | Nov 1995 | A |
5476502 | Rubin | Dec 1995 | A |
5483022 | Mar | Jan 1996 | A |
5484419 | Fleck | Jan 1996 | A |
5496354 | DeBellis | Mar 1996 | A |
5507787 | Borghi | Apr 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5545191 | Mann et al. | Aug 1996 | A |
5571159 | Alt | Nov 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5634899 | Shapland et al. | Jun 1997 | A |
5674217 | Wahlstrom et al. | Oct 1997 | A |
5755761 | Obino | May 1998 | A |
5755764 | Schroeppel | May 1998 | A |
5760341 | Laske et al. | Jun 1998 | A |
5772693 | Brownlee | Jun 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5800496 | Swoyer et al. | Sep 1998 | A |
5814076 | Brownlee | Sep 1998 | A |
5843132 | Ilvento | Dec 1998 | A |
5851206 | Guglielmi et al. | Dec 1998 | A |
5906207 | Shen | May 1999 | A |
5921935 | Hickey | Jul 1999 | A |
5935160 | Auricchio et al. | Aug 1999 | A |
5954761 | Machek et al. | Sep 1999 | A |
5997536 | Osswald et al. | Dec 1999 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6056742 | Murphy-Chutorian et al. | May 2000 | A |
6132390 | Cookston et al. | Oct 2000 | A |
6156061 | Wallace et al. | Dec 2000 | A |
6161029 | Spreigl et al. | Dec 2000 | A |
6167315 | Coe et al. | Dec 2000 | A |
6178354 | Gibson | Jan 2001 | B1 |
6183469 | Thapliyal et al. | Feb 2001 | B1 |
6238390 | Tu et al. | May 2001 | B1 |
6241727 | Tu et al. | Jun 2001 | B1 |
6272379 | Fischell et al. | Aug 2001 | B1 |
6324434 | Coe et al. | Nov 2001 | B2 |
6366808 | Schroeppel et al. | Apr 2002 | B1 |
6379351 | Thapliyal et al. | Apr 2002 | B1 |
6397109 | Cammilli et al. | May 2002 | B1 |
6451016 | Karakozian | Sep 2002 | B1 |
6477402 | Lynch et al. | Nov 2002 | B1 |
6477427 | Stolz et al. | Nov 2002 | B1 |
6501983 | Natarajan et al. | Dec 2002 | B1 |
6512957 | Witte | Jan 2003 | B1 |
6540765 | Malacoff | Apr 2003 | B1 |
6569145 | Shmulewitz et al. | May 2003 | B1 |
6584362 | Scheiner et al. | Jun 2003 | B1 |
6638278 | Falwell et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6690970 | Taheri et al. | Feb 2004 | B1 |
6697676 | Dahl | Feb 2004 | B2 |
6709390 | Marie Pop | Mar 2004 | B1 |
6711436 | Duhaylongsod | Mar 2004 | B1 |
6711440 | Deal et al. | Mar 2004 | B2 |
6772014 | Coe et al. | Aug 2004 | B2 |
6813516 | Ujhelyi et al. | Nov 2004 | B2 |
6865420 | Kroll | Mar 2005 | B1 |
6909920 | Lokhoff et al. | Jun 2005 | B2 |
6950701 | Begemann et al. | Sep 2005 | B2 |
6980858 | Fuimaono et al. | Dec 2005 | B2 |
6988001 | Greatbatch et al. | Jan 2006 | B2 |
6994314 | Garnier et al. | Feb 2006 | B2 |
6999809 | Currier et al. | Feb 2006 | B2 |
6999821 | Jenney et al. | Feb 2006 | B2 |
7003350 | Denker et al. | Feb 2006 | B2 |
7029467 | Currier et al. | Apr 2006 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7295874 | Prinzen et al. | Nov 2007 | B2 |
7422585 | Eggers et al. | Sep 2008 | B1 |
7499756 | Bowe et al. | Mar 2009 | B2 |
7570981 | Peterson | Aug 2009 | B2 |
7917210 | Baynham et al. | Mar 2011 | B2 |
7962208 | Shuros et al. | Jun 2011 | B2 |
7979123 | Prinzen et al. | Jul 2011 | B2 |
8027723 | Pastore et al. | Sep 2011 | B2 |
8214040 | Pastore et al. | Jul 2012 | B2 |
8244352 | Eidenschink et al. | Aug 2012 | B2 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020042632 | Iaizzo et al. | Apr 2002 | A1 |
20020072777 | Lu | Jun 2002 | A1 |
20020095067 | Guenst et al. | Jul 2002 | A1 |
20020116028 | Greatbatch et al. | Aug 2002 | A1 |
20020116029 | Miller et al. | Aug 2002 | A1 |
20020116033 | Greatbatch et al. | Aug 2002 | A1 |
20020116034 | Miller et al. | Aug 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20030004549 | Hill et al. | Jan 2003 | A1 |
20030009189 | Gilson et al. | Jan 2003 | A1 |
20030045908 | Condie et al. | Mar 2003 | A1 |
20030060854 | Zhu | Mar 2003 | A1 |
20030078471 | Foley et al. | Apr 2003 | A1 |
20030109901 | Greatbatch | Jun 2003 | A1 |
20030125774 | Salo | Jul 2003 | A1 |
20030139778 | Fischell et al. | Jul 2003 | A1 |
20030158583 | Burnett et al. | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030204206 | Padua et al. | Oct 2003 | A1 |
20030204231 | Hine et al. | Oct 2003 | A1 |
20030212361 | Boyle et al. | Nov 2003 | A1 |
20030229386 | Rosenman et al. | Dec 2003 | A1 |
20030233130 | Padmanabhan et al. | Dec 2003 | A1 |
20040010189 | van Sloun et al. | Jan 2004 | A1 |
20040015081 | Kramer et al. | Jan 2004 | A1 |
20040015204 | Whitehurst et al. | Jan 2004 | A1 |
20040038947 | Wink et al. | Feb 2004 | A1 |
20040088017 | Sharma et al. | May 2004 | A1 |
20040106960 | Siejko et al. | Jun 2004 | A1 |
20040116994 | De Bellis | Jun 2004 | A1 |
20040133247 | Stahmann et al. | Jul 2004 | A1 |
20040162599 | Kurth | Aug 2004 | A1 |
20040172081 | Wang | Sep 2004 | A1 |
20040214148 | Salvino et al. | Oct 2004 | A1 |
20040215139 | Cohen | Oct 2004 | A1 |
20040255956 | Vinten-Johansen et al. | Dec 2004 | A1 |
20040267326 | Ocel | Dec 2004 | A1 |
20050004476 | Payvar et al. | Jan 2005 | A1 |
20050038345 | Gorgenberg et al. | Feb 2005 | A1 |
20050075673 | Warkentin et al. | Apr 2005 | A1 |
20050119545 | Swanson | Jun 2005 | A1 |
20050137483 | Fischell et al. | Jun 2005 | A1 |
20050137631 | Yu et al. | Jun 2005 | A1 |
20050137647 | Wallace et al. | Jun 2005 | A1 |
20050143780 | Henry et al. | Jun 2005 | A1 |
20050149155 | Scheiner et al. | Jul 2005 | A1 |
20050197674 | McCabe et al. | Sep 2005 | A1 |
20050222632 | Obino | Oct 2005 | A1 |
20050251239 | Wallace et al. | Nov 2005 | A1 |
20050288717 | Sunagawa | Dec 2005 | A1 |
20050288763 | Andreas et al. | Dec 2005 | A1 |
20060009830 | Atkinson et al. | Jan 2006 | A1 |
20060036306 | Heist et al. | Feb 2006 | A1 |
20060058597 | Machado et al. | Mar 2006 | A1 |
20060100639 | Levin et al. | May 2006 | A1 |
20060100669 | Fuimaono et al. | May 2006 | A1 |
20060116593 | Zhang et al. | Jun 2006 | A1 |
20060136049 | Rojo | Jun 2006 | A1 |
20060142660 | Maschke | Jun 2006 | A1 |
20060142812 | Ortega et al. | Jun 2006 | A1 |
20060149326 | Prinzen et al. | Jul 2006 | A1 |
20060178586 | Dobak | Aug 2006 | A1 |
20060184191 | O'Brien | Aug 2006 | A1 |
20060195038 | Carlson et al. | Aug 2006 | A1 |
20060241357 | Chirife | Oct 2006 | A1 |
20060241704 | Shuros et al. | Oct 2006 | A1 |
20060241733 | Zhang et al. | Oct 2006 | A1 |
20060241736 | Haldeman | Oct 2006 | A1 |
20060247700 | Jackson | Nov 2006 | A1 |
20060253156 | Pastore et al. | Nov 2006 | A1 |
20060259085 | Zhang et al. | Nov 2006 | A1 |
20060259087 | Baynham et al. | Nov 2006 | A1 |
20060259088 | Pastore et al. | Nov 2006 | A1 |
20060287684 | Baynham et al. | Dec 2006 | A1 |
20060293741 | Johnson et al. | Dec 2006 | A1 |
20070021789 | Pastore et al. | Jan 2007 | A1 |
20070054871 | Pastore et al. | Mar 2007 | A1 |
20070055334 | Haldeman et al. | Mar 2007 | A1 |
20070100410 | Lamson et al. | May 2007 | A1 |
20070150005 | Sih et al. | Jun 2007 | A1 |
20070150009 | Kveen et al. | Jun 2007 | A1 |
20070233200 | Maschke | Oct 2007 | A1 |
20080058757 | Pajunk et al. | Mar 2008 | A1 |
20080071315 | Baynham et al. | Mar 2008 | A1 |
20080082136 | Gaudiani | Apr 2008 | A1 |
20080109063 | Hancock et al. | May 2008 | A1 |
20080114408 | Shuros et al. | May 2008 | A1 |
20080288030 | Zhang et al. | Nov 2008 | A1 |
20080319502 | Sunagawa et al. | Dec 2008 | A1 |
20090005845 | David et al. | Jan 2009 | A1 |
20090143835 | Pastore et al. | Jun 2009 | A1 |
20090318943 | Eidenschink et al. | Dec 2009 | A1 |
20090318984 | Mokelke et al. | Dec 2009 | A1 |
20090318989 | Tomaschko et al. | Dec 2009 | A1 |
20090318990 | Tomaschko et al. | Dec 2009 | A1 |
20090318991 | Tomaschko et al. | Dec 2009 | A1 |
20090318992 | Eidenschink et al. | Dec 2009 | A1 |
20090318993 | Eidenschink et al. | Dec 2009 | A1 |
20090318994 | Eidenschink et al. | Dec 2009 | A1 |
20100056858 | Mokelke et al. | Mar 2010 | A1 |
20100130913 | Baynham et al. | May 2010 | A1 |
20110137363 | Baynham et al. | Jun 2011 | A1 |
20110144709 | Baynham et al. | Jun 2011 | A1 |
Number | Date | Country |
---|---|---|
2459408 | Mar 2003 | CA |
3300050 | Jul 1984 | DE |
1690566 | Aug 2006 | EP |
5245215 | Sep 1993 | JP |
7504597 | May 1995 | JP |
2002514478 | May 2002 | JP |
2004533297 | Nov 2004 | JP |
2006-516451 | Jul 2006 | JP |
2011524787 | Sep 2011 | JP |
WO-9518649 | Jul 1995 | WO |
WO-9958191 | Nov 1999 | WO |
WO-0115609 | Mar 2001 | WO |
WO-03035139 | May 2003 | WO |
WO-2004012811 | Feb 2004 | WO |
WO-2004058326 | Jul 2004 | WO |
WO-2004058326 | Jul 2004 | WO |
WO-2004096290 | Nov 2004 | WO |
WO-2005000206 | Jan 2005 | WO |
WO-2005042083 | May 2005 | WO |
WO-2005065771 | Jul 2005 | WO |
WO-2006060586 | Jun 2006 | WO |
WO-2006115693 | Nov 2006 | WO |
WO-2006115693 | Nov 2006 | WO |
WO-2006116205 | Nov 2006 | WO |
WO-2006124636 | Nov 2006 | WO |
WO-2006124636 | Nov 2006 | WO |
WO-2006124729 | Nov 2006 | WO |
WO-2006124729 | Nov 2006 | WO |
WO-2007133962 | Nov 2007 | WO |
WO-2007133962 | Nov 2007 | WO |
WO-2008027261 | Mar 2008 | WO |
WO-2009154730 | Dec 2009 | WO |
WO-2009154720 | Dec 2009 | WO |
Entry |
---|
“U.S. Appl. No. 11/030,575, Non-Final Office Action mailed Jul. 26, 2006”, 10 pgs. |
“U.S. Appl. No. 11/030,575, Response filed Oct. 26, 2006 to Non Final Office Action mailed Jul. 26, 2006”, 8 pgs. |
“U.S. Appl. No. 11/113,828, Advisory Action mailed Feb. 2, 2010”, 3 pgs. |
“U.S. Appl. No. 11/113,828, Examiner Interview Summary received Feb. 4, 2011”, 1 pg. |
“U.S. Appl. No. 11/113,828, Final Office Action mailed Jun. 29, 2009”, 11 pgs. |
“U.S. Appl. No. 11/113,828, Final Office Action mailed Nov. 24, 2009”, 13 pgs. |
“U.S. Appl. No. 11/113,828, Non-Final Office Action mailed Mar. 5, 2008”, 8 pgs. |
“U.S. Appl. No. 11/113,828, Non-Final Office Action mailed Dec. 22, 2008”, 10 pgs. |
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Feb. 4, 2011”, 7 pgs. |
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Oct. 19, 2010”, 4 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Jan. 25, 2010 to Final Office Action mailed Nov. 24, 2009”, 8 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Jan. 28, 2008 to Restriction Requirement mailed Dec. 26, 2007”, 7 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Mar. 23, 2009 to Non-Final Office Action mailed Dec. 22, 2008”, 8 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Jun. 5, 2008 to Non-Final Office Action mailed Mar. 5, 2008”, 8 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Oct. 29, 2009 to Final Office Action mailed Jun. 29, 2009”, 9 pgs. |
“U.S. Appl. No. 11/113,828, Response filed Nov. 17, 2008 to Final Office Action mailed Sep. 17, 2008”, 11 pgs. |
“U.S. Appl. No. 11/113,828, Restriction Requirement mailed Dec. 26, 2007”, 8 pgs. |
“U.S. Appl. No. 11/129,050, Advisory Action mailed Jul. 14, 2009”, 3 pgs. |
“U.S. Appl. No. 11/129,050, Examiner Interview Summary mailed Feb. 11, 2009”, 2 pgs. |
“U.S. Appl. No. 11/129,050, Final Office Action mailed Apr. 21, 2009”, 10 pgs. |
“U.S. Appl. No. 11/129,050, Final Office Action mailed May 12, 2008”, 8 pgs. |
“U.S. Appl. No. 11/129,050, Non-Final Office Action mailed Nov. 6, 2008”, 7 pgs. |
“U.S. Appl. No. 11/129,050, Non-Final Office Action mailed Nov. 26, 2007”, 7 pgs. |
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Apr. 1, 2010”, 6 pgs. |
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Jul. 16, 2010”, 4 pgs. |
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Aug. 24, 2009”, 7 pgs. |
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Dec. 2, 2009”, 4 pgs. |
“U.S. Appl. No. 11/129,050, Response filed Feb. 23, 2009 to Non-Final Office Action mailed Nov. 6, 2008”, 13 pgs. |
“U.S. Appl. No. 11/129,050, Response filed Feb. 26, 2008 to Non-Final Office Action mailed Nov. 26, 2007”, 14 pgs. |
“U.S. Appl. No. 11/129,050, Response filed Jun. 22, 2009 to Final Office Action mailed Apr. 21, 2009”, 9 pgs. |
“U.S. Appl. No. 11/129,050, Response filed Jul. 14, 2008 to Final Office Action mailed May 12, 2008”, 13 pgs. |
“U.S. Appl. No. 11/129,050, Response filed Sep. 28, 2007 to Restriction Requirement mailed Aug. 1, 2007”, 11 pgs. |
“U.S. Appl. No. 11/129,050, Supplemental Amendment and Response filed Sep. 12, 2008 to Final Office Action mailed May 12, 2008 and the Advisory Action mailed Jul. 28, 2008”, 12 pgs. |
“U.S. Appl. No. 11/129,058, Advisory Action mailed Oct. 17, 2010”, 3 pgs. |
“U.S. Appl. No. 11/129,058, Appeal Brief filed Jan. 8, 2008”, 23 pgs. |
“U.S. Appl. No. 11/129,058, Decision on Appeal mailed Nov. 4, 2009”, 15 pgs. |
“U.S. Appl. No. 11/129,058, Examiner's Answer to Appeal Brief mailed Jun. 18, 2008”, 14 pgs. |
“U.S. Appl. No. 11/129,058, Final Office Action mailed Jul. 9, 2007”, 12 pgs. |
“U.S. Appl. No. 11/129,058, Non-Final Office Action mailed Jan. 29, 2007”, 11 pgs. |
“U.S. Appl. No. 11/129,058, Office Communication mailed Jan. 15, 2010”, 2 pgs. |
“U.S. Appl. No. 11/129,058, Response filed Apr. 30, 2007 to Non Final Office Action mailed Jan. 29, 2007”, 16 pgs. |
“U.S. Appl. No. 11/129,058, Response filed Oct. 9, 2007 to Final Office Action mailed Jul. 9, 2007”, 14 pgs. |
“U.S. Appl. No. 11/382,849, Final Office Action mailed Jan. 28, 2010”, 7 pgs. |
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed May 12, 2010”, 5 pgs. |
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed Aug. 31, 2009”, 8 pgs. |
“U.S. Appl. No. 11/382,849, Response filed Apr. 26, 2010 to Final Office Action mailed Jan. 28, 2010”, 10 pgs. |
“U.S. Appl. No. 11/382,849, Response filed Jun. 8, 2009 to Restriction Requirement mailed May 6, 2009”, 8 pgs. |
“U.S. Appl. No. 11/382,849, Response filed Aug. 2, 2010 to Non Final Office Action mailed May 12, 2010”, 7 pgs. |
“U.S. Appl. No. 11/382,849, Response filed Nov. 30, 2009 to Non Final Office Action mailed Aug. 31, 2009”, 11 pgs. |
“U.S. Appl. No. 11/382,849, Restriction Requirement mailed May 6, 2009”, 6 pgs. |
“U.S. Appl. No. 11/468,875, Advisory Action mailed Aug. 19, 2010”, 3 pgs. |
“U.S. Appl. No. 11/468,875, Final Office Action mailed Jun. 1, 2009”, 6 pgs. |
“U.S. Appl. No. 11/468,875, Non-Final Office Action mailed Dec. 11, 2008”, 8 pgs. |
“U.S. Appl. No. 11/468,875, Response filed Mar. 9, 2009 to Non-Final Office Action mailed Dec. 11, 2008”, 10 pgs. |
“U.S. Appl. No. 11/468,875, Response filed Sep. 1, 2009 to Advisory Action mailed Aug. 19, 2009 and the Final Office Action mailed Jun. 1, 2009”, 9 pgs. |
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Mar. 24, 2010”, 7 pgs. |
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Sep. 17, 2010”, 4 pgs. |
“Arrow Bipolar Pacing Catheters and Pacing Kits”, Arrow International, (2000), 4 pgs. |
“Australian Application Serial No. 2007290672, First Examiner Report Received mailed Aug. 23, 2010”, 2 pgs. |
“Coronary Dilatation Catheters”, online]. [archived Mar. 3, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060303151627/http://www.guidant.com/products/TemplatePDFs/NoPriceDilataticatheters.pdf>, (2006), 3 pgs. |
“European Application Serial No. 06740227.1, Communication dated Dec. 27, 2007”, 2 pgs. |
“European Application Serial No. 06740227.1, Response filed Jan. 27, 2008 to Communication dated Dec. 27, 2007”, 9 pgs. |
“European Application Serial No. 06752527.9, Communication mailed Mar. 8, 2010”, 6 pgs. |
“European Application Serial No. 06752527.9, Response filed Jul. 7, 2010 to Office Action dated Mar. 8, 2010”, 15 pgs. |
“European Application Serial No. 06752527.9, Summons to Attend Oral Proceedings Received mailed Jul. 23, 2010”, 3 pgs. |
“European Application Serial No. 06752540.2, Communication Mar. 3, 2008”, 2 pgs. |
“European Application Serial No. 06752540.2, Communication mailed Mar. 8, 2010”, 2 pgs. |
“European Application Serial No. 06752540.2, Response filed Apr. 9, 2008 to Communication Mar. 3, 2008”, 6 pgs. |
“European Application Serial No. 06752540.2, Response filed Jul. 15, 2010 to Communication mailed Mar. 8, 2010”, 20 pgs. |
“European Application Serial No. 06762527.9, Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 2 pgs. |
“European Application Serial No. 06762527.9, Response filed Apr. 9, 2008 to Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 6 pgs. |
“European Application Serial No. 07797336.0, Communication mailed Mar. 10, 2010”, 3 pgs. |
“European Application Serial No. 07797336.0, Office Action mailed Feb. 24, 2009”, 4 pgs. |
“European Application Serial No. 07797336.0, Response filed Jul. 6, 2009 to Communication mailed Feb. 24, 2009”, 20 pgs. |
“European Application Serial No. 07797336.0, Response filed Jul. 7, 2010 to Office Action dated Mar. 10, 2010”, 5 pgs. |
“European Application Serial No. 07837205.9, Communication dated Apr. 8, 2009”, 2 pgs. |
“Guidant Product Catalog”, [online]. [archived Feb. 4, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050204225345/http://guidant.com/products/VIproductcatalog.pdf>, (2005), 133 pgs. |
“International Application Serial No. PCT/US/2009/003589, International Search Report mailed Sep. 14, 2009”, 5 pgs. |
“International Application Serial No. PCT/US/2009/003589, Written Opinion mailed Sep. 14, 2009”, 11 pgs. |
“International Application Serial No. PCT/US2006/018497, International Search Report mailed Oct. 24, 2006”, 5 pgs. |
“International Application Serial No. PCT/US2006/018497, Written Opinion mailed Oct. 24, 2006”, 7 pgs. |
“International Application Serial No. PCT/US2006/018642, International Search Report mailed Oct. 24, 2006”, 5 pgs. |
“International Application Serial No. PCT/US2006/018642, Written Opinion mailed Oct. 24, 2006”, 7 pgs. |
“International Application Serial No. PCT/US2006/018642,, International Search Report and Written Opinion mailed Oct. 24, 2006”, 14 pgs. |
“International Application Serial No. PCT/US2007/018577, International Search Report mailed Jan. 15, 2008”, 4 pgs. |
“International Application Serial No. PCT/US2007/018577, Written Opinion mailed Jan. 15, 2008”, 7 pgs. |
“International Application Serial No. PCT/US2007/068217, International Search Report mailed Oct. 30, 2007”, 5 pgs. |
“International Application Serial No. PCT/US2007/068217, Written Opinion mailed Oct. 30, 2007”, 8 pgs. |
“International Application Serial No. PCT/US2009/003575, International Search Report mailed Sep. 14, 2009”, 6 pgs. |
“International Application Serial No. PCT/US2009/003575, Written Opinion mailed Sep. 14, 2009”, 9 pgs. |
“International Application Serial No. PCT/US2009/003577, International Search Report mailed Aug. 9, 2009”, 5 pgs. |
“International Application Serial No. PCT/US2009/003577, Written Opinion mailed Aug. 9, 2009”, 10 pgs. |
“International Application Serial No. PCT/US2009/003581, International Search Report mailed Sep. 21, 2009”, 5 pgs. |
“International Application Serial No. PCT/US2009/003581, Written Opinion mailed Sep. 21, 2009”, 10 pgs. |
“International Application Serial No. PCT/US2009/003590, International Search Report mailed Sep. 14, 2009”, 5 pgs. |
“International Application Serial No. PCT/US2009/003590, Written Opinion mailed Sep. 14, 2009”, 10 pgs. |
“International Application Serial No. PCT/US2009/003594, International Search Report mailed Sep. 17, 2009”, 5 pgs. |
“International Application Serial No. PCT/US2009/003594, Written Opinion mailed Sep. 17, 2009”, 9 pgs. |
“International Search Report and Written Opinion for Application No. PCT/US2006/011972 mailed Oct. 6, 2006”, 16 pgs. |
“Japanese Application Serial No. 2008-511421, Voluntary Amendment filed Apr. 27, 2009”, (w/ English Translation of Amended Claims), 11 pgs. |
“Japanese Application Serial No. 2008-511452, Voluntary Amendment filed May 11, 2009”, (w/ English Translation of Amended Claims), 8 pgs. |
“Japanese Application Serial No. 2009-510093, Voluntary Amendment filed Jan. 14, 2009”, 4 pgs. |
“Product Overview: RX ACCULINK Carotid Stent System: RX ACCUNET Embolic Protection System”, [online]. [retrieved Apr. 14, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060414151850/http://www.guidant.com/webapp/emarketing/ppt/acculink/ACCULINK.pdf>, (2005), 23 pgs. |
“RX ACCUNET Embolic Protection System”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/ES/accunet.shtml>, (2006), 4 pgs. |
“RX ACCUNET Embolic Protection System: Information for Prescribers”, [online]. [archived Feb. 5, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050205044138/http://guidant.com/products/TemplatePDFs/ACCUNET—RX.pdf, (Jan. 6, 2005), 32 pgs. |
“Voyager RX Coronary Dilatation Catheter”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/VI/RX—US—Voyager—Intro.shtml>, (2006), 2 pgs. |
Airaksinen, K. E., et al., “Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty”, J Am Coll Cardiol., 29(5), (Apr. 1997), 1035-1038. |
Brockway, Marina V, et al., “Method and Apparatus for Delivering Chronic and Post-Ischemia Cardiac Therapies”, U.S. Appl. No. 11/207,251, filed Aug. 19, 2005, 40 pgs. |
Girouard, Steven D., “Pulmonary Vein Stent for Treating Atrial Fibrillation”, U.S. Appl. No. 60/298,741, filed Jun. 15, 2001, 14 pgs. |
Heinroth, K. M, et al., “Temporary transcoronary pacing by coated guidewires”, Clin Res Cardiol., 95, (2006), 1-6. |
Henriques, Jose P., et al., “Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours”, J Am Coll Cardiol, 41(12), (Jun. 18, 2003), 2138-2142. |
Kin, Hajime, et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion”, Cardiovascular Research, 62(1), (Apr. 1, 2004), 74-85. |
Kis, A., “Repeated cardiac pacing extends the time during which canine hearts are protected against ischaemia-induced arrhythmias : role of nitric oxide.”, Journal of Molecular and Cellular Cardiology, 31(6), (Jun. 1999), 1229-1241. |
Koning, M M, “Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels”, Circulation, 93(1), (Jan. 1, 1996), 178-186. |
Meier, B., et al., “Coronary Pacing During Percutaneous Transluminal Coronary Angioplasty”, Circulation, 71(3), (Mar. 1985), 557-561. |
Murry, C. E., et al., “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium”, Circulation, 74(5), (1986), 1124-1136. |
Ovize, M., et al., “Stretch preconditions canine myocardium.”, Am J Physiol., 266(1 Pt 2), (Jan. 1994), H137-46. |
Pastore, Joseph M, et al., “Intermittent Stress Augmentation Pacing for Cardioprotective Effect”, U.S. Appl. No. 11/458,286, filed Jul. 18, 2006, 23 pgs. |
Rosa, A., et al., “Ectopic Pacing at Physiological Rate Improves Postanoxic Recovery of the Developing Heart”, Am. J. Physiol.—Heart Circ. Physiol., 284, (2003), H2384-H2392. |
Tsang, A., et al., “Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway”, Circ Res., 95(3), Epub Jul. 8, 2004, (Aug. 6, 2004), 230-2. |
Vanagt, W. Y. R., et al., “Ventricular Pacing for Improving Myocardial Tolerance to Ischemia”, Progress Report on Project Guidant-CARIM, (Oct. 2003), 1-25. |
Vegh, A, et al., “Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning”, Cardiovascular Research, 25(12), (Dec. 1991), 1051-3. |
Wu, Zhong-Kai, et al., “Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization”, Circulation, 106(24), (Dec. 10, 2002), 3091-3096. |
Yang, S. M., et al., “Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways”, Journal of the American College of Cardiology, 44(5), (Sep. 1, 2004), 1103-1110. |
Zhao, et al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning”, Am J Physiol Heart Circ Physiol, 285(2), (Aug. 2003), H579-H588. |
“U.S. Appl. No. 13/029,631, Notice of Allowance mailed Aug. 24, 2012”, 7 pgs. |
“U.S. Appl. No. 11/113,828, Final Office Action mailed Sep. 17, 2008”, 10 pgs. |
“U.S. Appl. No. 11/468,875, Response filed Aug. 3, 2009 to Final Office Action mailed Jun. 1, 2009”, 8 pgs. |
“U.S. Appl. No. 12/322,382, Advisory Action mailed Nov. 8, 2011”, 3 pgs. |
“U.S. Appl. No. 12/322,382, Final Office Action mailed Aug. 25, 2011”, 12 pgs. |
“U.S. Appl. No. 12/322,382, Non Final Office Action mailed Mar. 21, 2011”, 14 pgs. |
“U.S. Appl. No. 12/322,382, Response filed Jun. 21, 2011, to Non Final Office Action mailed Mar. 21, 2011”, 16 pgs. |
“U.S. Appl. No. 12/322,382, Response filed Oct. 24, 2011 to Final Office Action mailed Aug. 25, 2011”, 15 pgs. |
“U.S. Appl. No. 12/694,328, Response filed Oct. 19, 2011 to Non Final Office Action mailed Aug. 19, 2011”, 13 pgs. |
“U.S. Appl. No. 12/694,328, Response filed Nov. 21, 2011 to Advisory Action mailed Oct. 28, 2011”, and Non Final Office Action mailed Aug. 19, 2011, 13 pgs. |
“U.S. Appl. No. 12/694,328, Advisory Action mailed Oct. 28, 2011”, 3 pgs. |
“U.S. Appl. No. 12/694,328, Final Office Action mailed Aug. 19, 2011”, 12 pgs. |
“U.S. Appl. No. 12/694,328, Non Final Office Action mailed Feb. 8, 2011”, 13 pgs. |
“U.S. Appl. No. 12/694,328, Response filed Jun. 8, 2011 to Non Final Office Action mailed Feb. 8, 2011”, 12 pgs. |
“Australian Application Serial No. 2007290672, Response filed Mar. 17, 2011 to Non Final Office Action mailed Aug. 23, 2011”, 11. |
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 13, 2012”, English Translation only, 5 pgs. |
“Chinese Application Serial No. 200780032286.X, Response filed Jun. 28, 2011, to Non Final Office Action dated Feb. 23, 2011”, (w/English Translation), 15 pgs. |
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 23, 2011”, 5 pgs. |
“European Application Serial No. 06740227.1, Office Action mailed Mar. 10, 2011”, 4 pgs. |
“European Application Serial No. 06740227.1, Response filed Jul. 12, 2011 to Office Action dated Mar. 10, 2011”, 15 pgs. |
“Japanese Application Serial No. 2008-508872, Office Action mailed Oct. 27, 2011”, 6 pgs. |
“Japanese Application Serial No. 2008-508872, Response filed Jan. 31, 2012, to Office Action mailed Oct. 31, 2011”, W/English Translation, 14 pgs. |
“Japanese Application Serial No. 2008-511421, Office Action mailed Nov. 16, 2011”, (w/ English Translation), 5 pgs. |
“Japanese Application Serial No. 2008-511452, Office Action mailed Nov. 14, 2011”, 4 pgs. |
“Japanese Application Serial No. 2008-511452, Response filed Feb. 14, 2012 to Office Action mailed Nov. 14, 2011”, (English Translation of Claims), 3 pgs. |
“U.S. Appl. No. 12/484,727, Non Final Office Action mailed Feb. 13, 2012”, 7 pgs. |
“U.S. Appl. No. 12/484,727, Response filed Jun. 12, 2012 to Non Final Office Action mailed Feb. 13, 2002”, 10 pgs. |
“U.S. Appl. No. 12/484,727, Response filed Jan. 23, 2012 to Restriction Requirement mailed Dec. 23, 2011”, 6 pgs. |
“U.S. Appl. No. 12/484,727, Restriction Requirement mailed Dec. 23, 2011”, 7 pgs. |
“U.S. Appl. No. 12/484,804, Final Office Action mailed Jun. 5, 2012”, 10 pgs. |
“U.S. Appl. No. 12/484,804, Response filed May 3, 2012 to Non-Final Office Action mailed Feb. 6, 2012”, 12 pgs. |
“U.S. Appl. No. 12/484,804, Response filed Dec. 14, 2011 to Restriction Requirement mailed Nov. 14, 2011”, 7 pgs. |
“U.S. Appl. No. 12/484,804, Restriction Requirement mailed Nov. 14, 2011”, 8 pgs. |
“U.S. Appl. No. 12/484,804, Non Final Office Action mailed Feb. 6, 2012”, 8 pgs. |
“European Application Serial No. 09767033.5, Office Action mailed Apr. 15, 2011”, 1 pg. |
“European Application Serial No. 09767033.5, Response filed May 18, 2011 to Office Action mailed Apr. 15, 2011”, 7 pgs. |
“European Application Serial No. 09767033.5, Response filed Dec. 5, 2011 to Office Action mailed Aug. 2, 2011”, 10 pgs. |
“European Application Serial No. 09767043.4, Office Action mailed Apr. 14, 2011”, 1 pg. |
“European Application Serial No. 09767043.4, Response filed May 24, 2011 to Office Action mailed Apr. 14, 2011”, 13 pgs. |
“European Application Serial No. 09767033.5, Examination Notification Art 94(3) mailed Aug. 2, 2011”, 6 pgs. |
“International Application Serial No. PCT/US2009/003577, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 12 pgs. |
“International Application Serial No. PCT/US2009/003590, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 9 pgs. |
“Japanese Application Serial No. 2011-514591, Voluntary Amendment filed Jan. 12, 2011”, (w/ English Translation), 11 pgs. |
“Japanese Application Serial No. 2011-514594, Voluntary Amendment filed Jan. 18, 2011”, (w/ English Translation of Amended Claims), 49 pgs. |
“U.S. Appl. No. 13/019,888, Notice of Allowance mailed Nov. 6, 2012”, 8 pgs. |
“U.S. Appl. No. 13/019,888, Response filed Sep. 28, 2012 to Non Final Office Action mailed Jun. 29, 2012”, 10 pgs. |
Number | Date | Country | |
---|---|---|---|
20110230928 A1 | Sep 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11113828 | Apr 2005 | US |
Child | 13113706 | US |